Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
SynAct Pharma AB ( (SE:SYNACT) ) has shared an announcement.
SynAct Pharma AB announced the conversion of 1,000,000 warrants by Heights Capital Management, generating SEK 17.7 million. This financial boost strengthens SynAct’s financial position, extending its operational runway into 2027 and enhancing its ability to pursue development opportunities and engage with potential partners.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm. The company specializes in resolving inflammation through the selective activation of the melanocortin system. It offers a range of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activity, aiding patients in achieving immune balance.
Average Trading Volume: 222,948
Current Market Cap: SEK1.09B
For a thorough assessment of SYNACT stock, go to TipRanks’ Stock Analysis page.